|
注册号: Registration number: |
ChiCTR2400084286 |
|
最近更新日期: Date of Last Refreshed on: |
2024-05-14 10:53:37 |
|
注册时间: Date of Registration: |
2024-05-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
眼科手术开放式通气面罩在PDR术中应用效果和安全性的评价:一项随机对照研究 |
|
Public title: |
Evaluation of the application effect and safety of open ventilation masks in ophthalmic surgery during PDR: A randomized controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
眼科手术开放式通气面罩在PDR术中应用效果和安全性的评价:一项随机对照研究 |
|
Scientific title: |
Evaluation of the application effect and safety of open ventilation masks in ophthalmic surgery during PDR: A randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
戴瑞 |
研究负责人: |
李甦雁 |
|
Applicant: |
Dai rui |
Study leader: |
Li Suyan |
|
申请注册联系人电话: Applicant telephone: |
+86 159 9678 5301 |
研究负责人电话:
Study leader's |
+86 138 5210 1775 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dairui-1986@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lisuyan1226@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
徐州市铜山区大学路269号 |
研究负责人通讯地址: |
徐州市铜山区大学路269号 |
|
Applicant address: |
269 Daxue Road, Tongshan District, Xuzhou City |
Study leader's address: |
269 Daxue Road, Tongshan District, Xuzhou City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
徐州市第一人民医院 |
||
|
Applicant's institution: |
Xuzhou First People's Hospital |
||
|
研究负责人所在单位: |
徐州市第一人民医院 |
||
|
Affiliation of the Leader: |
Xuzhou First People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
xyyll[2024]065号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
徐州市第一人民医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Review Committee of Xuzhou First People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-08 00:00:00 | ||
|
伦理委员会联系人: |
李泳 |
||
|
Contact Name of the ethic committee: |
Li Yong |
||
|
伦理委员会联系地址: |
徐州市铜山区大学路269号 |
||
|
Contact Address of the ethic committee: |
269 Daxue Road, Tongshan District, Xuzhou City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 516 6816 7579 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
徐州市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xuzhou First People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
徐州市铜山区大学路269号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
269 Daxue Road, Tongshan District, Xuzhou City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self selected topic(raise independently) |
||||||||||||||||||||||
|
研究疾病: |
糖尿病视网膜病变 |
||||||||||||||||||||||
|
Target disease: |
Diabetes retinopathy |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较分析眼科手术开放式通气面罩吸氧与传统鼻导管吸氧在糖网患者行玻璃体视网膜手术中应用效果,为眼科手术开放式通气面罩在眼科手术中的广泛应用提供一定的参考价值 |
||||||||||||||||||||||
|
Objectives of Study: |
Comparative analysis of the application effects of open ventilation mask oxygen therapy and traditional nasal cannula oxygen therapy in vitreoretinal surgery for diabetic retinopathy patients, providing certain reference value for the widespread application of open ventilation mask in ophthalmic surgery |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)严重心功能不全,最近6个月内发生心脑血管意外; (2)严重肝肾功能不全; (3)凝血功能异常者; (4)患眼存在其他视网膜和脉络膜疾病或其他眼部疾病(青光眼、高度近视等),影响手术结果; (5)手术眼既往有玻璃体视网膜手术史; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Severe cardiac insufficiency, with cardiovascular and cerebrovascular accidents occurring within the past 6 months; (2) Severe liver and kidney dysfunction; (3) Individuals with abnormal coagulation function; (4) The presence of other retinal and choroidal diseases or other eye diseases (glaucoma, high myopia, etc.) in the affected eye can affect the surgical results; (5) History of vitreoretinal surgery in the surgical eye; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-05-11 00:00:00至 To 2024-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-05-14 00:00:00 至 To 2024-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
根据随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
According to the random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲 |
|
Blinding: |
Single blind |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |